论文部分内容阅读
目的:探讨益髓补肾方改善恶性淋巴瘤化疗患者相关性贫血临床疗效,观察其对免疫功能的影响。方法:选取河北省中医院血液病科2010年1月—2015年12月收治的恶性淋巴瘤化疗相关性贫血患者110例,按随机数字表法分为对照组和治疗组,各55例,对照组常规化疗;治疗组在常规化疗基础上予以益髓补肾方(1剂/d)口服治疗,治疗15 d为1疗程,共治疗2个疗程。两组采血测定血常规,记录生活质量,同时比较临床疗效及并发症。结果:对照组总有效率为69.09%,治疗组有效率为89.09%,治疗组优于对照组(P<0.05);与治疗前比较,两组治疗后血红蛋白(Hb),血细胞比容(Hct),红细胞计数(RBC)含量升高(P<0.05),促红细胞生成素(EPO)含量降低(P<0.05);治疗后躯体、角色、社会、情绪等指标评分升高(P<0.05);治疗后与对照组比较,治疗组治疗后Hb,Hct,RBC含量较高,EPO含量降低,治疗后躯体、角色、社会、情绪等评分升高(P<0.05);治疗组T淋巴细胞亚群CD3~+,CD4~+,CD4~+/CD8~+水平升高,CD8~+细胞水平下降(P<0.05);对照组不良反应发生率为12.73%,治疗组不良反应发生率为7.27%,治疗组低于对照组(P<0.05)。结论:益髓补肾方治疗恶性淋巴瘤化疗相关性贫血疗效确切,可提高生活质量及患者免疫功能,具有较好的增效减毒作用。
Objective: To investigate the clinical efficacy of Yisu Bushen Decoction in improving the related anemia in patients with malignant lymphoma and to observe its effect on immune function. Methods: A total of 110 patients with chemotherapy-related anemia of malignant lymphoma who were admitted to Department of Hematology, Hebei Hospital of Traditional Chinese Medicine from January 2010 to December 2015 were selected and divided into control group and treatment group according to random number table. The patients in the treatment group were treated with Yishen Bushen Fang (1 dose / d) orally on the basis of routine chemotherapy. The treatment for 15 days was a course of treatment for a total of 2 courses of treatment. Blood samples were taken from two groups to measure blood quality, and quality of life was recorded. At the same time, clinical efficacy and complications were compared. Results: The total effective rate of the control group was 69.09%, the effective rate of the treatment group was 89.09%, and the treatment group was superior to the control group (P <0.05). Compared with before treatment, the Hb, Hct (P <0.05) and the content of erythropoietin (EPO) decreased (P <0.05). After treatment, the scores of somatosensory, social, emotional and emotional indicators increased (P <0.05) After treatment, the levels of Hb, Hct, RBC and EPO in the treatment group were significantly lower than those in the control group (P <0.05). After treatment, the scores of T lymphocyte subsets The levels of CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + were increased and the levels of CD8 ~ + cells were decreased (P <0.05). The incidence of adverse reactions in the control group was 12.73%, and the incidence of adverse reactions in the treatment group was 7.27 %, The treatment group was lower than the control group (P <0.05). Conclusion: Yishen Bushen Fang treatment of malignant lymphoma chemotherapy-related anemia curative effect, can improve the quality of life and immune function, with better synergistic effect attenuated.